Loading...
NPI 1215914288 · Research Triangle Park, NC · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratory Corporation Of America Holdings is a clinical medical laboratory provider located in Research Triangle Park, North Carolina. This profile covers 143 Medicare and 236 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratory Corporation Of America Holdings |
| Address | 1904 Tw Alexander Dr |
| City | Research Triangle Park |
| State | NC |
| ZIP | 27709 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 29, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $115.7M |
| Medicare | $9.6M |
LABORATORY CORPORATION OF AMERICA HOLDINGS operates as a high-volume clinical laboratory with a clear toxicology emphasis: its Medicare top CPT/HCPCS include G0483 (14.5K claims, $3.3M revenue), 80307 (41.9K claims, $2.5M revenue), and G0481 (14.4K claims, $2.2M revenue), and Medicaid volumes are even larger with 80307 (1.5M claims, $55.2M revenue), G0480 (346.5K claims, $19.4M revenue), and G0481 (154.1K claims, $9.2M revenue). The code mix and claim counts indicate a core business built around presumptive and definitive drug testing workflows rather than point-of-care or single-test services.
Revenue concentration is extreme in toxicology: the provider’s precomputed top 3 Medicare codes account for 84.7% of its Medicare revenue, and the top 3 Medicaid codes account for 78.5% of its Medicaid revenue. These shares show the organization’s financial performance is heavily dependent on a small set of high-volume drug-testing codes, which concentrates operational and reimbursement risk around those services.
The payer mix is heavily skewed toward Medicaid in scale: lifetime Medicaid revenue is $115.7M compared with $9.6M in Medicare. While the provider bills both programs, the absolute dollar gap indicates it is effectively Medicaid-dominant in terms of revenue exposure and market activity.
National competitive standing for Medicare toxicology is dominant: G0483 ranks #6 of 1063 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), 80307 ranks #3 of 4760 providers nationally (100th percentile; extreme outlier), and G0481 ranks #4 of 1766 providers nationally (100th percentile; extreme outlier). Those ranks and the “extreme outlier” labels indicate volumes for these codes are far above typical national peers and position the provider as a major national player in definitive and presumptive drug testing.
State-level competitive standing in Medicaid mirrors its national role for toxicology: 80307 ranks #2 of 362 providers in-state (100th percentile; extreme outlier), G0480 ranks #2 of 149 providers in-state (99th percentile; extreme outlier), and G0481 ranks #2 of 84 providers in-state (99th percentile; extreme outlier). These placements show the provider is among the largest in-state lab vendors for both presumptive and definitive drug testing services.
Beyond toxicology, the provider also delivers measurable volumes in genetic and prenatal testing and infectious disease screening under Medicaid, signaling service-line breadth. Examples include 81220 (10.3K claims, $3M revenue; ranks #5 of 26 in-state) and 81420 (5.3K claims, $2.3M revenue; ranks #6 of 15 in-state), plus high-volume STI/HIV testing such as 87491 (59.8K claims, $1.4M revenue) and 87591 (60.5K claims, $1.4M revenue), which rank in the top deciles of state peers.
Unit-level reimbursement and volume patterns differ between payers: for 80307 the Medicare average paid per claim is $60 (41.9K claims) while Medicaid shows $36 avg paid per claim but at far greater scale (1.5M claims, $55.2M revenue). This combination of lower Medicaid unit rates and vastly higher claim counts underscores a business model that relies on scale in Medicaid to drive Medicaid revenue dominance.
The provider’s NPI tenure (enumerated 2005-12-29, ~21 years ago) indicates an established operation with sustained participation in federal and state payer programs. Long-standing enrollment combined with the outsized volumes and rankings for key toxicology codes suggests institutional capacity to support high-throughput laboratory contracts and sustained payer relationships.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
143 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 14,450 | $230 | $3.3M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 41,860 | $60 | $2.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 14,440 | $150 | $2.2M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6,970 | $110 | $753.2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,390 | $190 | $461.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 3,460 | $10 | $34.6K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 4,030 | $10 | $32.2K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 2,240 | $10 | $29.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 1,610 | $20 | $25.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 2,720 | $10 | $21.7K |
Showing 1–10 of 143
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 143 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
236 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,534,380 | $40 | $55.2M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 346,540 | $60 | $19.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 154,060 | $60 | $9.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 59,120 | $100 | $6M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 10,270 | $290 | $3M |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 5,270 | $440 | $2.3M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16,680 | $90 | $1.6M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 59,840 | $20 | $1.4M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 60,460 | $20 | $1.4M |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 43,350 | $20 | $866.9K |
Showing 1–10 of 236
How this provider's Medicaid billing volume and revenue compare to other North Carolina providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. North Carolina median
236 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 6 | 20 | 240 | $400 | $13.6M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 5 | 30 | 170 | $260 | $2.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 112 | 160 | 840 | $70 | $2.3M |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 3 | 10 | 1,360 | $150 | $1.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7 | 110 | 1,450 | $110 | $1.7M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 8 | 40 | 480 | $40 | $1.4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 14 | 80 | 420 | $30 | $1.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6 | 60 | 1,640 | $100 | $940.2K |
| 86003 | The lab analyst performs the technical lab test to analyze a specimen such as serum for allergen–specific immunoglobulin E (IgE), using a crude allergen extract. The test result is quantitative or… | 27 | 40 | 220 | $60 | $920.5K |
| 80081 | The lab analyst performs an obstetric panel; this panel must include tests for a complete blood count with differential, a hepatitis B surface antigen test, a single–result test for HIV–1 antigens… | 3 | 10 | 2,000 | $40 | $905.6K |
Showing 1–10 of 236
Other providers in the same ZIP code as Laboratory Corporation Of America Holdings, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Laboratory Corporation Of America Holdings | NC | Clinical Medical Laboratory | $3.5M | $281.4M |
| Laboratory Corporation Of America Holdings | NC | Clinical Medical Laboratory | $2.7M | $53.2M |
| Integrated Laboratory Solutions | NC | Clinical Medical Laboratory | $51.4K | $563.7K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.